Simple skin test may spot Parkinson's risk years early

NCT ID NCT07428447

Recruiting now Knowledge-focused Sponsor: CND Life Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This study is testing whether a skin biopsy can detect abnormal proteins linked to Parkinson's disease in people with essential tremor, a common movement disorder. Researchers will follow 300 participants aged 50-85 for two years to see who develops Parkinson's. The goal is to find a simple, less invasive way to identify those at highest risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Syn-One Test (skin biopsy for phosphorylated alpha-synuclein)
What this could lead to: If successful, this could lead to a simple skin test that identifies which people with essential tremor are at high risk of developing Parkinson's disease, enabling earlier monitoring or intervention.
What could go wrong: This is an observational study, not a treatment trial. The test may not accurately predict progression, and results may not apply to all patients. It is still early, with only 300 participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL TREMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential tremor movement disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESSENTIAL TREMOR ESSENTIAL TREMOR, MOVEMENT DISORDERS ESSENTIAL TREMOR-PLUS

Contacts and locations

Locations

CND Clinical Research Center
RECRUITING

Scottsdale, Arizona, 85258, United States
Veracity Neurosciences LLC
RECRUITING

Memphis, Tennessee, 38157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.